What Is Medication-Assisted Treatment?
Medication-assisted treatment (MAT) is the use of FDA-approved medications, in combination with counseling and behavioral therapies, to treat opioid use disorder. It is considered the gold standard of care by the Substance Abuse and Mental Health Services Administration (SAMHSA), the National Institute on Drug Abuse (NIDA), and the World Health Organization (WHO).
MAT addresses the neurochemical changes described in our guide to opiate addiction and opioid use disorder. It is not "replacing one drug with another," as critics sometimes claim. The medications used in MAT are carefully dosed to reduce cravings, prevent withdrawal, and stabilize brain chemistry without producing the euphoria or impairment associated with opioid misuse. Think of it as analogous to insulin for diabetes or antihypertensives for high blood pressure: a medical intervention that manages a chronic condition.
The evidence supporting MAT is extensive. Studies consistently show that MAT reduces opioid use and overdose deaths, improves retention in treatment programs, decreases criminal activity associated with drug-seeking, reduces the transmission of infectious diseases like HIV and hepatitis C, and improves social functioning and employment outcomes.
The Three FDA-Approved Medications
Methadone
How it works: Methadone is a long-acting full opioid agonist, meaning it activates the same opioid receptors as heroin or prescription painkillers but does so slowly and steadily. When taken as prescribed, methadone prevents withdrawal symptoms and reduces cravings without producing a significant high.
Administration: Methadone for opioid use disorder must be dispensed through federally regulated opioid treatment programs (OTPs), commonly known as methadone clinics. Patients typically start with daily supervised dosing and may earn take-home doses as they demonstrate stability.
Effectiveness: Methadone is one of the most studied medications in addiction medicine. Research spanning over 50 years shows it reduces illicit opioid use, decreases overdose risk, improves treatment retention, and supports long-term recovery. It is particularly effective for individuals with severe, long-standing opioid use disorder.
Considerations: The requirement for daily clinic visits, particularly during the early phase of treatment, can be a barrier for people with transportation challenges, work schedules, or childcare responsibilities. Methadone also carries a risk of overdose if misused, particularly in combination with benzodiazepines or alcohol.
Buprenorphine (Suboxone, Subutex, Sublocade)
How it works: Buprenorphine is a partial opioid agonist, meaning it activates opioid receptors but produces a weaker effect than full agonists. It has a "ceiling effect," where increasing the dose beyond a certain point does not increase its effects, making it safer than methadone in terms of overdose risk.
Suboxone combines buprenorphine with naloxone, an opioid antagonist that is included to discourage injection misuse. Sublocade is a monthly injectable formulation that eliminates the need for daily dosing.
Administration: Unlike methadone, buprenorphine can be prescribed by qualified physicians, nurse practitioners, and physician assistants in office-based settings. This significantly improves access, as patients can fill prescriptions at regular pharmacies rather than attending specialized clinics.
Effectiveness: Buprenorphine is highly effective at reducing opioid use, preventing withdrawal, and supporting recovery. Its safety profile, combined with the convenience of office-based prescribing, has made it the most widely prescribed MAT medication in the United States.
Considerations: Buprenorphine must be initiated after the patient has entered early opiate withdrawal to avoid precipitated withdrawal, a rapid and intense reaction that occurs when buprenorphine displaces other opioids from receptors. Proper timing of the first dose is essential.
Naltrexone (Vivitrol)
How it works: Naltrexone is an opioid antagonist, meaning it blocks opioid receptors entirely rather than activating them. If a person takes opioids while on naltrexone, they will not experience euphoria or pain relief. This blocking effect reduces the reinforcement that drives continued use.
Vivitrol is an extended-release injectable formulation administered once monthly. An oral formulation also exists but is less commonly used due to adherence challenges.
Administration: Naltrexone does not require special licensing or clinic settings. Any healthcare provider can prescribe it. The monthly Vivitrol injection is particularly convenient as it eliminates daily medication adherence concerns.
Effectiveness: Naltrexone is effective for highly motivated individuals who have already completed detox and are committed to abstinence. It is particularly useful for people in the criminal justice system, healthcare professionals, and others for whom opioid agonist therapy may not be appropriate.
Considerations: The main limitation of naltrexone is that the patient must be fully detoxed (7 to 14 days opioid-free) before starting treatment. This gap creates a high-risk period for relapse. Additionally, if a patient stops taking naltrexone and relapses, their reduced tolerance means the risk of fatal overdose is elevated, especially given the prevalence of fentanyl in the current drug supply.
Comparing MAT Medications
| Factor | Methadone | Buprenorphine | Naltrexone |
|---|---|---|---|
| Mechanism | Full agonist | Partial agonist | Antagonist |
| Setting | OTP clinic only | Office-based | Any provider |
| Dosing | Daily (initially) | Daily or monthly | Monthly (Vivitrol) |
| Detox required first | No | Partial withdrawal | Full detox |
| Overdose risk | Moderate | Low (ceiling effect) | None (blocks opioids) |
| Best for | Severe OUD, long history | Moderate to severe OUD | Motivated, post-detox |
Access and Barriers
Despite overwhelming evidence supporting MAT, significant barriers to access remain.
Geographic Disparities
Many rural areas lack opioid treatment programs and have few buprenorphine-prescribing providers. Patients in these areas may need to travel hours for treatment, a barrier that disproportionately affects low-income individuals and those without reliable transportation. Telehealth has helped bridge some of this gap, with many states now allowing buprenorphine initiation via video visits.
Insurance and Cost
Most insurance plans, including Medicaid and Medicare, are required to cover MAT. However, prior authorization requirements, limited provider networks, and high copays can still create barriers. For uninsured individuals, SAMHSA-funded programs and community health centers may offer low-cost or free treatment. Use FindTreatment.gov to locate nearby providers.
The monthly cost of MAT varies. Methadone clinic fees typically range from $200 to $400 per month. Generic buprenorphine/naloxone can cost $100 to $300 per month with insurance. Vivitrol injections are significantly more expensive, often $1,000 to $1,500 per month, though manufacturer assistance programs and insurance coverage can reduce out-of-pocket costs.
Stigma Within the Treatment System
Perhaps the most frustrating barrier is stigma from within the healthcare and recovery communities themselves. Some treatment programs, sober living homes, and even 12-step groups discourage or prohibit MAT use, despite evidence that it saves lives. Some employers and drug courts treat MAT medications as equivalent to illicit drug use. These attitudes are slowly changing as education and advocacy efforts increase.
How Long Should MAT Continue?
There is no predetermined timeline for MAT. Current clinical guidelines, including the ASAM Criteria for patient placement, recommend that treatment continue for as long as the patient benefits from it. For many people, this means years or even lifelong maintenance.
Research shows that discontinuing MAT is associated with increased rates of relapse and overdose. The decision to taper off medication should be made collaboratively between the patient and provider, based on stability, support systems, and individual risk factors, not based on arbitrary time limits.
Some patients successfully taper off MAT after one to two years of stability. Others maintain MAT indefinitely and live full, productive lives while doing so. Both paths are valid. For a broader look at all available approaches, see our opiate and opioid treatment options overview.